NHS England has quietly removed a high profile claim from its website asserting that 137 hospital trusts were benefiting from Palantir’s artificial intelligence data system. The move follows revelations that nearly thirty of those institutions were not actually utilizing the majority of the technology, contradicting official narratives about how deeply the Federated Data Platform had been integrated into frontline healthcare. While health officials initially promoted the tool as a way to slash administration and speed up patient discharges, the discrepancy between their public lists and reality has sparked fresh accusations of exaggeration.
The controversy arrives at a critical juncture as government ministers consider extending the three hundred and thirty million pound contract until 2029. Critics, including members of Parliament and various doctors’ unions, argue that the scale of the project’s success has been systematically overstated. These concerns have already caught the attention of the Office for Statistics Regulation, which previously cautioned that there was little evidence to back up claims that the software helped facilitate over one hundred thousand additional surgical operations.
Beyond the disputes over efficacy, Palantir faces significant ideological opposition due to its ties to billionaire Peter Thiel and its work with international military and immigration agencies. Opponents describe the firm as a surveillance entity and warn that relying on an American corporation for sensitive medical records compromises national sovereignty. Some lawmakers are now urging the government to scrap the deal entirely in favor of an open platform developed by British tech firms, suggesting that continuing with Palantir threatens public trust in how health data is managed.
While Palantir maintains that terminating its partnership would prioritize politics over patient care, labor unions and advocacy groups remain steadfast in their demand for an exit strategy. They suggest using existing contractual clauses to phase out the technology by 2027 rather than granting an extension. As lobbyists push for deeper integration under the guise of building technological capability, skeptics worry that giving the company more time will only make it harder to ever remove them from the heart of the health service.
